AstraZeneca Announced Enhertu Approved In China For Patients With Previously Treated HER2-Positive Advanced Or Metastatic Gastric Cancer
AstraZeneca Announced Enhertu Approved In China For Patients With Previously Treated HER2-Positive Advanced Or Metastatic Gastric Cancer
阿斯利康宣佈恩賜圖獲批用於中國先前接受過治療的HER2陽性晚期或轉移性胃癌患者。
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has received conditional approval in China as a monotherapy for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received two or more prior treatment regimens.
阿斯利康和第一三共的愛文思肝癌射（曲妥珠單抗-雜醇酸酯）獲得中國條件批准，作爲單藥治療，用於治療局部晚期或轉移性HER2陽性胃癌或胃食管連接處腺癌患者，這些患者已接受兩個或兩個以上的先前治療方案。